Patients receiving care for advanced cancer at Moores Cancer Center at UC San Diego Health were more likely to survive or experience a longer period without their disease progressing if they received personalized cancer therapy, report University of California San Diego School of Medicine researchers.
… Read More
Led by Razelle Kurzrock, MD, director of the Center for Personalized Cancer Therapy at Moores Cancer Center and senior author of the study, a multidisciplinary molecular tumor board was established to advise treating physicians on course of care using an individual patient’s molecular tumor makeup to design precision medicine strategies.
“Patients who underwent a molecular tumor board-recommended therapy were better matched to genomic alterations in their cancer and had improved outcomes,” said Kurzrock. “The three-year survival for patients with the highest degree of matching and who received a personalized cancer therapy was approximately 55 percent compared to 25 percent in patients who received therapy that
… Read More
This month’s cache of Insights & Outcomes includes a map of the human retina, a menu of African savanna diets, and a much-deserved honor for a Yale chemist.
As always, you can find more science and medicine research news on YaleNews’ Science & Technology and Health & Medicine pages.
John C. Tully wins Zewail Prize in Molecular Sciences
John C. Tully, Sterling Emeritus Professor of Chemistry and professor of physics and applied physics, is the winner of the 8th Ahmed Zewail Prize in Molecular Sciences. The prize, developed by the international journal Chemical Physical Letters and the scientific information publisher Elsevier, is awarded biennially to a scientist who has made “significant and creative contributions, particularly those of a fundamental nature, to any of the disciplines of molecular sciences.” Prize officials said Tully was chosen for his “development and insightful application of powerful theoretical tools to elucidate the motions of
… Read More
Marketers have been chasing lower CPM (cost per thousand) prices, particularly in programmatic channels, thinking that leads to greater “efficiency” in their digital ad spending. That is wrong and it’s just a race to the bottomless pit of ad fraud and adtech middlemen taking a greater and greater share of every dollar spent by the marketer.
Real, mainstream publishers with real reporters and editors create real content for real human audiences. They cannot afford to sell ad impressions at very low prices. But fake sites and app publishers can afford to sell ads at very low CPMs because they have no cost of content and low operating costs — think piracy sites, bot generated sites, etc. Those bot generated sites have no human audiences because they don’t need humans. They just use bot traffic to create billions of impressions to sell through programmatic exchanges to unsuspecting advertisers.
Marketers have even
… Read More
Coronavirus has put the health of the UK population firmly at the top of everyone’s agenda. Daily statistics read out on the news detailing the impact of the virus is testament to the fact that patient outcomes now matter to us all.
Response from the NHS has been admirable; one of the world’s largest healthcare providers has done its best dealing with the pandemic effectively. Its systems, people and organisations have had a razor-sharp focus on tackling COVID-19. This has created a catalyst for change, accelerating the uptake of technology, use of data and collaboration across sectors.
“In the last six months, the focus on clinical outcomes and excellence has been unprecedented. This has happened at pace and at scale, with a renewed focus on the patient. There’s also been a real readiness to change during this pandemic. A huge number of stakeholders within the NHS want to do things
It saved lives in past epidemics of lung-damaging viruses. Now, the life-support option known as ECMO appears to be doing the same for many of the critically ill COVID-19 patients who receive it, according to a new international study.
… Read More
The 1,035 patients in the study faced a staggeringly high risk of death, as ventilators and other care failed to support their lungs. But after they were placed on ECMO, their actual death rate was less than 40%. That’s similar to the rate for patients treated with ECMO in past outbreaks of lung-damaging viruses, and other severe forms of viral pneumonia.
The new study published in The Lancet provides strong support for the use of ECMO — short for extracorporeal membrane oxygenation — in appropriate patients as the pandemic rages on worldwide.
It may help more hospitals that have ECMO capability understand which of their COVID-19 patients might benefit from the